Survival after an acute myocardial infarction (AMI) remains one of the basic indicators of the effectiveness of the treatment of this pathology. Despite the success of urgent treatment and secondary prevention of AMI, a significant number of patients develop chronic heart failure (HF), the course of which is associated with increased morbidity, mortality, and increased economic burden. Drug therapy, which is based on the use of four different groups of drugs, among which the main role is assigned to angiotensin-converting enzyme inhibitors and angiotensin-neprilysin receptor inhibitors, is recognized as an effective strategy for the management of such patients. The article examines in detail the results of the AIRE-S and PARADISE-MI studies, which analyzed the ability of ramipril to influence the life expectancy of patients with AMI and HF compared with placebo (AIRE-S) and sacubitril/valsartan (PARADISE-MI). As part of AIRE-S, the life expectancy of the specified cohort of patients has been proven to increase by an average of 13 months, with the maximum positive effect on the life expectancy of patients with concomitant diabetes, hypertension, and coronary heart disease. The PARADISE-MI study demonstrated that ramipril was not inferior to sacubitril/valsartan in the ability to protect patients with AMI, HF from cardiovascular death, occurrence and progression of HF (11.9% vs 13.2%, respectively; hazard ratio 0.90; 95% confidence interval 0.78–1.04; p=0.17).
Heidenreich P., Bozkurt B., Aguilar D. et al. (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18): e895–e1032. doi: 10.1161/CIR.0000000000001063.
McDonagh T., Metra M., Adamo M. et al. (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J., 42(36): 3599–3726. doi: 10.1093/eurheartj/ehab368.
Ibanez B., James S., Agewall S. et al. (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J., 39(2): 119–177. doi: 10.1093/eurheartj/ehx393.
O’Gara P., Kushner F., Ascheim D. et al. (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc. Interv., 82(1): E1–E27. doi: 10.1002/ccd.24776.
Wu J., Hall A., Gale C. et al. (2021) Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure. Heart, 7(5): 389–395.
Jering K., Claggett B., Pfeffer M. et al. (2021) Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur. J. Heart Fail., 23(6): 1040–1048.
McQueen M., Lonn E., Gerstein H. et al. (2005) The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand. J. Clin. Lab. Invest. Suppl., 240: 143–156.
Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 355(9200): 253–259.
Lonn E., Yusuf S., Hoogwerf B. et al. (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care, 25(11): 1919–1927. doi: 10.2337/diacare.25.11.1919.
DREAM Trial Investigators; Bosch J., Yusuf S., Gerstein H. et al. (2006) Effect of ramipril on the incidence of diabetes. N. Engl. J. Med., 355(15): 1551–1562. doi: 10.1056/NEJMoa065061.
Ruggenenti P., Perna A., Remuzzi G. (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol., 12(12): 2832–2837.
Mallamaci F., Ruggenenti P., Perna A. et al. (2011) REIN Study Group. ACE inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol., 22(6): 1122–1128.
Sun W., Zhang H., Guo J. et al. (2016) Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis. Medicine (Baltimore), 95(6): e2554.
Lang C., Arora R., Saha S., Molnar J. (2008) Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function. J. Cardiometab. Syndr., 3(1): 45–52.
Lubsen J., Chadha D., Yotof Y., Swedberg K. (1996) Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am. J. Cardiol., 77(14): 1191–1196.
Pfeffer M., Claggett B., Lewis E. et al. (2021) PARADISE-MI Investigators and Committees. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N. Engl. J. Med., 385(20): 1845–1855. doi: 10.1056/NEJMoa2104508.
Pfeffer M., Claggett B., Lewis E. e al. (2022) Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 145(1): 87–89.